VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | The potential use of CAR-T therapy following autologous transplantation in multiple myeloma

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, talks on the possibility of using BCMA-directed CAR-T therapy following autologous transplantation in patients with multiple myeloma who do not respond well to transplantation in order to prolong remission and prevent relapse. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter